Glaxosmithkline Share News (GSK)

No safety concerns yet in trials of GSK's Ebola vaccine

By Kate Kelland LONDON, Nov 17 (Reuters) - Almost 200 people have received GlaxoSmithKline's experimental Ebola vaccine in trials in the United States, Britain, Mali and Switzerland, and the safety data so far are "very satisfactory", scientists said on Monday. The trials, which began

BUZZ-U.S. Stocks on the Move-Geron, Baker Hughes, Abengoa, Petrobras, BlackBerry

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index e-mini futures inched up on Friday: Dow Jones ind

US private equity outfit to bid for GlaxoSmithKline´s mature drugs business

US private equity outfit Apollo Global Management is preparing to make a bid for all of GlaxoSmithKline's mature drugs, joining an auction which could see the business valued at over $3bn (£1.91bn), according to four people familiar with the process, Reuters reports. As of 20:05 the American Deposit

Glaxo Seeking Additional Indication For Eltrombopag In EMA Submission

UPDATE 1-Sanofi's dual-action biotech asthma drug performs well in test

(Adds detail on drug's other uses, Sanofi investor day) Nov 11 (Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effe

Sanofi's dual-action biotech asthma drug performs well in test

Nov 11 (Reuters) - An experimental biotech drug for severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism may be highly effective. Dupilumab is a latecomer among a new class of antibody drugs for p

RPT - INSIGHT-After hep C cure, companies target next big liver disease market

(Repeats for additional subscribers) By Bill Berkrot NEW YORK, Nov 10 (Reuters) - Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential mar

INSIGHT-After hep C cure, companies target next big liver disease market

By Bill Berkrot NEW YORK, Nov 9 (Reuters) - Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins,

Friday broker round-up UPDATE

AstraZeneca: Deutsche Bank increases target price from 4100p to 4350p and reiterates its hold recommendation. AVEVA: Societe Generale reduces target price from 2250p to 2000p, while keeping its buy recommendation. Big Yellow Group: Citi raises target price from 470p to 540p and maintains its neutra

UK BROKER RATINGS: Goldman Sachs Says Buy Royal Mail And Intertek

UPDATE 1-EU scheme commits $350 mln for research on Ebola vaccines, tests

* Work focuses on vaccines trials and manufacturing * Also new research into rapid diagnostic tests * EU ship sailing with ambulances, labs, other equipment (Adds details on shipment, more on diagnostic tests) By Ben Hirschler LONDON, Nov 6 (Reuters) - The Europe Union a

UK WINNERS & LOSERS: Supermarkets Gain As Morrisons Reports Progress

EU scheme commits $350 mln to research Ebola vaccines and tests

By Ben Hirschler LONDON, Nov 6 (Reuters) - The Europe Union and drugmakers pledged on Thursday to invest 280 million euros ($350 million) into Ebola research, with the lion's share going to fast-track the testing and manufacture of potential vaccines. The funding will go to projects b

BUZZ-Healthcare stocks: having an off day

** Healthcare stocks trade heavily in the red, accounting for more than half of the FTSE 100's points drop. ** UK benchmark down 0.3 pct. ** AstraZeneca falls 2.5 pct even after raising its 2014 sales forecast. ** Traders said drugmaker's results would have needed to have been q

MARKET COMMENT: UK Shares Weak As Investors Await ECB Decision